Skip to content

RadNet

US · RDNT #2019 by market cap Listed 1970
68.61 -1.67 -2.38%
Live - 5344 symbols - heartbeat 470s ago · 2026-10-07 19:54
After-hours 68.61 0.00%
Market cap
5.40B
P/E (TTM)
-263.88
P/B
4.93
EPS
-0.25
Reader sentiment Are you bullish or bearish on RDNT?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 5.04 In line with history 55th percentile
5-year average 4.89 · #23 of 40 in Diagnostics & Research
P/E ratio -269.92 Cheap vs history 25th percentile
5-year average 18.04 · forward 127.90
P/S ratio 2.43 Expensive vs history 69th percentile
5-year average 1.87 · forward 2.10 · #13 of 43 in Diagnostics & Research

Vs. peers Diagnostics & Research

Company Market cap P/E (TTM) P/B Div yield
RadNet (RDNT) 5.40B -263.88 4.93 0.00%
Thermo Fisher Scientific (TMO) 244.79B 35.63 4.65 0.27%
Danaher (DHR) 153.60B 38.81 2.92 0.66%
Natera (NTRA) 57.02B -293.01 31.30 0.00%
Agilent Technologies (A) 47.67B 33.35 6.47 0.60%
Waters (WAT) 42.84B 110.38 2.82 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value80.04 Economic moatNarrow UncertaintyHigh

Trading 16.7% below Morningstar's fair value estimate.

Fair value

RadNet Inc is assigned a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 12% discount to our quantitative fair value estimate of $80.04 per share; however, caution is warranted due to this estimate's high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The firm's balance sheet bolsters our quantitative valuation. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. Reflecting the firm's leverage is its EBITDA/interest coverage ratio of 4.7, which sits in the bottom 30% compared with peers globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be undervalued.

Conversely, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 0.9%, a core component of profitability, ranks in the bottom 40% compared with global peers. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

Economic moat

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.